Potential Therapeutic Effects of PPAR Ligands in Glioblastoma

Glioblastoma (GB), also known as grade IV astrocytoma, represents the most aggressive form of brain tumor, characterized by extraordinary heterogeneity and high invasiveness and mortality. Thus, a great deal of interest is currently being directed to investigate a new therapeutic strategy and in rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Basilotta, Rossella, Lanza, Marika, Casili, Giovanna, Chisari, Giulia, Munao, Stefania, Colarossi, Lorenzo, Cucinotta, Laura, Campolo, Michela, Esposito, Emanuela, Paterniti, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869892/
https://www.ncbi.nlm.nih.gov/pubmed/35203272
http://dx.doi.org/10.3390/cells11040621
_version_ 1784656603248590848
author Basilotta, Rossella
Lanza, Marika
Casili, Giovanna
Chisari, Giulia
Munao, Stefania
Colarossi, Lorenzo
Cucinotta, Laura
Campolo, Michela
Esposito, Emanuela
Paterniti, Irene
author_facet Basilotta, Rossella
Lanza, Marika
Casili, Giovanna
Chisari, Giulia
Munao, Stefania
Colarossi, Lorenzo
Cucinotta, Laura
Campolo, Michela
Esposito, Emanuela
Paterniti, Irene
author_sort Basilotta, Rossella
collection PubMed
description Glioblastoma (GB), also known as grade IV astrocytoma, represents the most aggressive form of brain tumor, characterized by extraordinary heterogeneity and high invasiveness and mortality. Thus, a great deal of interest is currently being directed to investigate a new therapeutic strategy and in recent years, the research has focused its attention on the evaluation of the anticancer effects of some drugs already in use for other diseases. This is the case of peroxisome proliferator-activated receptors (PPARs) ligands, which over the years have been revealed to possess anticancer properties. PPARs belong to the nuclear receptor superfamily and are divided into three main subtypes: PPAR-α, PPAR-β/δ, and PPAR-γ. These receptors, once activated by specific natural or synthetic ligands, translocate to the nucleus and dimerize with the retinoid X receptors (RXR), starting the signal transduction of numerous genes involved in many physiological processes. PPARs receptors are activated by specific ligands and participate principally in the preservation of homeostasis and in lipid and glucose metabolism. In fact, synthetic PPAR-α agonists, such as fibrates, are drugs currently in use for the clinical treatment of hypertriglyceridemia, while PPAR-γ agonists, including thiazolidinediones (TZDs), are known as insulin-sensitizing drugs. In this review, we will analyze the role of PPARs receptors in the progression of tumorigenesis and the action of PPARs agonists in promoting, or not, the induction of cell death in GB cells, highlighting the conflicting opinions present in the literature.
format Online
Article
Text
id pubmed-8869892
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88698922022-02-25 Potential Therapeutic Effects of PPAR Ligands in Glioblastoma Basilotta, Rossella Lanza, Marika Casili, Giovanna Chisari, Giulia Munao, Stefania Colarossi, Lorenzo Cucinotta, Laura Campolo, Michela Esposito, Emanuela Paterniti, Irene Cells Review Glioblastoma (GB), also known as grade IV astrocytoma, represents the most aggressive form of brain tumor, characterized by extraordinary heterogeneity and high invasiveness and mortality. Thus, a great deal of interest is currently being directed to investigate a new therapeutic strategy and in recent years, the research has focused its attention on the evaluation of the anticancer effects of some drugs already in use for other diseases. This is the case of peroxisome proliferator-activated receptors (PPARs) ligands, which over the years have been revealed to possess anticancer properties. PPARs belong to the nuclear receptor superfamily and are divided into three main subtypes: PPAR-α, PPAR-β/δ, and PPAR-γ. These receptors, once activated by specific natural or synthetic ligands, translocate to the nucleus and dimerize with the retinoid X receptors (RXR), starting the signal transduction of numerous genes involved in many physiological processes. PPARs receptors are activated by specific ligands and participate principally in the preservation of homeostasis and in lipid and glucose metabolism. In fact, synthetic PPAR-α agonists, such as fibrates, are drugs currently in use for the clinical treatment of hypertriglyceridemia, while PPAR-γ agonists, including thiazolidinediones (TZDs), are known as insulin-sensitizing drugs. In this review, we will analyze the role of PPARs receptors in the progression of tumorigenesis and the action of PPARs agonists in promoting, or not, the induction of cell death in GB cells, highlighting the conflicting opinions present in the literature. MDPI 2022-02-10 /pmc/articles/PMC8869892/ /pubmed/35203272 http://dx.doi.org/10.3390/cells11040621 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Basilotta, Rossella
Lanza, Marika
Casili, Giovanna
Chisari, Giulia
Munao, Stefania
Colarossi, Lorenzo
Cucinotta, Laura
Campolo, Michela
Esposito, Emanuela
Paterniti, Irene
Potential Therapeutic Effects of PPAR Ligands in Glioblastoma
title Potential Therapeutic Effects of PPAR Ligands in Glioblastoma
title_full Potential Therapeutic Effects of PPAR Ligands in Glioblastoma
title_fullStr Potential Therapeutic Effects of PPAR Ligands in Glioblastoma
title_full_unstemmed Potential Therapeutic Effects of PPAR Ligands in Glioblastoma
title_short Potential Therapeutic Effects of PPAR Ligands in Glioblastoma
title_sort potential therapeutic effects of ppar ligands in glioblastoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869892/
https://www.ncbi.nlm.nih.gov/pubmed/35203272
http://dx.doi.org/10.3390/cells11040621
work_keys_str_mv AT basilottarossella potentialtherapeuticeffectsofpparligandsinglioblastoma
AT lanzamarika potentialtherapeuticeffectsofpparligandsinglioblastoma
AT casiligiovanna potentialtherapeuticeffectsofpparligandsinglioblastoma
AT chisarigiulia potentialtherapeuticeffectsofpparligandsinglioblastoma
AT munaostefania potentialtherapeuticeffectsofpparligandsinglioblastoma
AT colarossilorenzo potentialtherapeuticeffectsofpparligandsinglioblastoma
AT cucinottalaura potentialtherapeuticeffectsofpparligandsinglioblastoma
AT campolomichela potentialtherapeuticeffectsofpparligandsinglioblastoma
AT espositoemanuela potentialtherapeuticeffectsofpparligandsinglioblastoma
AT paternitiirene potentialtherapeuticeffectsofpparligandsinglioblastoma